Veru (VERU) Jefferies Global Healthcare Conference summary

Leadership transition and strategic positioning

• CEO transition planned as company is well-positioned for growth, with strong business units and leadership team in place.

• Recent cost structure and infrastructure changes align with growth and profitability goals.

• Transformation from semiconductor equipment to a pure-play life science tools company over the past decade.

Integration, margin initiatives, and business transformation

• Over 15 acquisitions in 10 years; focus now on integration and leveraging 45 sites for scalable growth.

• Site rationalization and portfolio optimization are key to improving margins.

• B Medical business refocused on core vaccine cold chain, targeting low single-digit growth and 20% EBITDA margin after exiting less strategic lines.

• Luxembourg facility to be repurposed for more strategic products, enhancing profitability.

Regional performance and market dynamics

• China multi-omics business achieved four consecutive quarters of double-digit growth, driven by investment, talent, and consultative approach.

• New facility construction in Suzhou reflects confidence in continued growth and capacity needs.

• Geopolitical risks monitored; gene synthesis capability can shift from China to U.S. if needed, with existing U.S. capacity.